Boehringer launches Phase IIa trial for diabetic retinopathy

Boehringer Ingelheim has launched a Phase IIa clinical trial (ROBIN) of its product candidate BI 1467335 to treat patients with non-proliferative diabetic retinopathy (NPDR).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news